“Increasing Use of Immune Checkpoint Inhibitor”
The global adrenocortical carcinoma (ACC) treatment market is experiencing steady growth due to advancements in targeted therapies and immunotherapy. A significant trend in this market is the increasing use of immune checkpoint inhibitors such as nivolumab, which have shown promising results in improving survival rates for patients with metastatic or advanced ACC. For instance, nivolumab has been used in clinical trials to enhance the immune response against ACC cells, leading to better treatment outcomes. In addition, the adoption of personalized medicine is driving tailored treatment approaches, enabling healthcare providers to optimize therapy based on genetic and molecular profiling of the tumor. Mitotane, a chemotherapy agent, remains a core treatment, but its combination with newer therapies such as nivolumab and radiation therapy offers more effective results. As early diagnosis improves through advanced imaging techniques such as CT scans and MRIs, patients are increasingly receiving timely and accurate treatments, contributing to the growth and innovation in the ACC treatment market.
